• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Global Penny Stocks To Consider In December 2025

    Simply Wall St·12/30/2025 09:05:18
    Listen to the news

    As global markets continue to show resilience, with U.S. stocks reaching record highs and optimism surrounding artificial intelligence bolstering sentiment, investors are keenly observing opportunities across various sectors. Amid this backdrop, penny stocks remain a compelling area for exploration due to their potential for significant returns when backed by strong financials. Despite the term's somewhat outdated nature, these smaller or newer companies can offer unique value propositions that larger firms may overlook.

    Top 10 Penny Stocks Globally

    Name Share Price Market Cap Rewards & Risks
    Lever Style (SEHK:1346) HK$1.48 HK$915.41M ✅ 4 ⚠️ 1 View Analysis >
    Foresight Group Holdings (LSE:FSG) £4.28 £491.52M ✅ 5 ⚠️ 0 View Analysis >
    IVE Group (ASX:IGL) A$3.00 A$456.46M ✅ 4 ⚠️ 2 View Analysis >
    TK Group (Holdings) (SEHK:2283) HK$2.57 HK$2.13B ✅ 4 ⚠️ 1 View Analysis >
    Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ✅ 4 ⚠️ 2 View Analysis >
    West African Resources (ASX:WAF) A$3.14 A$3.54B ✅ 4 ⚠️ 2 View Analysis >
    Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD3.44 SGD13.54B ✅ 5 ⚠️ 1 View Analysis >
    Integrated Diagnostics Holdings (LSE:IDHC) $0.715 $415.65M ✅ 4 ⚠️ 2 View Analysis >
    DXN Holdings Bhd (KLSE:DXN) MYR0.51 MYR2.54B ✅ 5 ⚠️ 0 View Analysis >
    Begbies Traynor Group (AIM:BEG) £1.145 £184.26M ✅ 6 ⚠️ 1 View Analysis >

    Click here to see the full list of 3,607 stocks from our Global Penny Stocks screener.

    Let's explore several standout options from the results in the screener.

    3D Medicines (SEHK:1244)

    Simply Wall St Financial Health Rating: ★★★★★☆

    Overview: 3D Medicines Inc. is a biopharmaceutical company focused on researching, developing, and commercializing oncology products for cancer treatment in the People's Republic of China, with a market cap of approximately HK$1.17 billion.

    Operations: The company generates revenue primarily from its biopharmaceutical research and development segment, totaling CN¥448.39 million.

    Market Cap: HK$1.17B

    3D Medicines Inc., with a market cap of approximately HK$1.17 billion, focuses on oncology products in China and generates revenue mainly from biopharmaceutical R&D, totaling CN¥448.39 million. Despite being unprofitable, the company has reduced its losses by 36.7% annually over five years and maintains a stable weekly volatility of 9%. Its seasoned management team and board provide experienced oversight, while the company's short-term assets cover both short- and long-term liabilities comfortably. Additionally, it holds more cash than total debt, ensuring a sufficient cash runway for over a year based on current free cash flow trends.

    SEHK:1244 Financial Position Analysis as at Dec 2025
    SEHK:1244 Financial Position Analysis as at Dec 2025

    Anton Oilfield Services Group (SEHK:3337)

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: Anton Oilfield Services Group is an investment holding company that provides integrated oilfield technology services in the People’s Republic of China, Iraq, and internationally, with a market cap of HK$21.60 billion.

    Operations: There are no specific revenue segments reported for Anton Oilfield Services Group.

    Market Cap: HK$2.16B

    Anton Oilfield Services Group, with a market cap of HK$21.60 billion, has shown consistent profitability growth over the past five years, increasing earnings annually by 36.7%. Recent earnings for the nine months ended September 2025 reported sales of CNY 3,690.9 million and net income of CNY 229.93 million. The company's debt management is robust, with a reduced debt to equity ratio now at 26.5%, and its short-term assets significantly exceed both short- and long-term liabilities. However, its return on equity remains low at 4.4%, and profit margins have declined from last year’s figures despite high-quality earnings stability.

    SEHK:3337 Revenue & Expenses Breakdown as at Dec 2025
    SEHK:3337 Revenue & Expenses Breakdown as at Dec 2025

    Sino-Synergy Hydrogen Energy Technology (Jiaxing) (SEHK:9663)

    Simply Wall St Financial Health Rating: ★★★★★☆

    Overview: Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd. focuses on the research, development, production, and sale of hydrogen fuel cell stacks and systems in China, with a market cap of HK$2.49 billion.

    Operations: The company generates revenue of CN¥368.31 million from its Batteries / Battery Systems segment.

    Market Cap: HK$2.49B

    Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd., with a market cap of HK$2.49 billion, focuses on hydrogen fuel cell stacks and systems. Despite being unprofitable with a negative return on equity of -13.56%, the company maintains financial stability through its substantial cash reserves, which exceed its total debt and cover both short- and long-term liabilities comfortably. The management team and board are experienced, averaging tenures over three years. While earnings have declined by 1.9% annually over five years, the company's cash runway is secure for more than three years under current free cash flow conditions without shareholder dilution in the past year.

    SEHK:9663 Financial Position Analysis as at Dec 2025
    SEHK:9663 Financial Position Analysis as at Dec 2025

    Summing It All Up

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.